Peanut Oral Immunotherapy: Is It Safer in Preschoolers than in Older Age Groups?
- 6 November 2019
- journal article
- editorial
- Published by Elsevier BV in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (8), 2768-2769
- https://doi.org/10.1016/j.jaip.2019.07.027
Abstract
No abstract availableFunding Information
- Boston Children's Hospital
- Aimmune Therapeutics
- End Allergy Together
- Broad-MIT
- Translational Research Program
This publication has 15 references indexed in Scilit:
- Prevalence and Severity of Food Allergies Among US AdultsJAMA Network Open, 2019
- AR101 Oral Immunotherapy for Peanut AllergyNew England Journal of Medicine, 2018
- Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by OmalizumabThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical TrialThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- The emotional, social, and financial burden of food allergies on children and their familiesAllergy and Asthma Proceedings, 2017
- The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future DirectionsCurrent Allergy and Asthma Reports, 2016
- Food allergy: Epidemiology, pathogenesis, diagnosis, and treatmentJournal of Allergy and Clinical Immunology, 2014
- Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3)Journal of Allergy and Clinical Immunology, 2014
- Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapyJournal of Allergy and Clinical Immunology, 2013
- The Prevalence, Severity, and Distribution of Childhood Food Allergy in the United StatesPediatrics, 2011